Sanofi’s quadrivalent flu vaccine approved by US FDA
The FDA has approved Sanofi Pasteur’s supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent.
Sanofi Pasteur is the vaccines division of Sanofi. Like the division’s Fluzone vaccine, which is administered to over 50 million people in the US each year, Fluzone Quadrivalent is licensed for use in children six months of age and older, adolescents and adults.
Fluzone Quadrivalent includes two A strains and two B strains to help protect against influenza disease. It will be available in the US in time for the 2013 influenza season.
David Greenberg, MD, Vice President U.S. Scientific and Medical Affairs, Sanofi Pasteur.
Sanofi’s 4-in-1 influenza vaccine joins GlaxoSmithKline’s Fluarix Quadrivalent and AstraZeneca’s MedImmune FluMist Quadrivalent that are already approved for use in the United States.
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.